摘要
目的:探讨吉非替尼(商品名易瑞沙)治疗非小细胞肺癌的疗效和毒副反应。方法:回顾性分析2005～2009年本院46例单药吉非替尼250mg治疗复治的非小细胞肺癌患者至少4周,并获得随访,评价总生存时间,疾病控制率,无进展生存期,药物毒副反应。结果:总生存时间为9个月,疾病控制率为66%,无进展生存期为6.6个月,未出现Ⅲ度、Ⅳ度药物毒性反应。结论:吉非替尼可以显著改善非小细胞肺癌临床症状和生活质量,且耐受性好,是一种适合我国人民的靶向治疗药物。
Objective：To ascertain clinical experience and toxic reactions of treating non-small cell lung cancer（NSCLC） by gefitinib.Methods：Clinic data of 46 cases NSCLC were collected analyzed treated by gefitinib from 2005-2007.Evaluation were made about curative effect,quality of life,mediun survive time,time to progression,toxic action.Results：Mean survive time of all patients was 9 months,total clinic control rate was 66%.Time to prograss was 6.6 months.Ⅲ-Ⅳ grades of toxic reaction were not founded.Conclusion：Gefitinib may obviously improve the clinical symptom and QOL of NSCLC patients.It is a kind of molecule-tagets medicient suited with Chinese.
出处
《中国当代医药》
2010年第36期62-63,共2页
China Modern Medicine
关键词
吉非替尼
非小细胞肺癌
疗效观察
Gefitinib
Non-small cell lung cancer
Effect observation
